Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Recasts Keytruda Regulatory Strategy In Head & Neck Cancer To Capitalize On KEYNOTE-048

30 Oct 2018

• By Bridget Silverman

Turn arrow Road sign — Merck says this is a good sign for Keytruda.

Related Content

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

25 Jul 2017

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

30 Jul 2018

Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

12 Aug 2016

Related Companies

Merck & Co., Inc.

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.